Yes, Monitor Transaminases During Tigecycline Treatment
Tigecycline, a glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia, carries a risk of elevated liver enzymes, including transaminases (ALT and AST). Labeling and guidelines recommend monitoring transaminases before and during therapy, especially in patients with liver impairment or prolonged use.[1][2]
Why Does Tigecycline Affect Transaminases?
Tigecycline can cause asymptomatic transaminase elevations in up to 15-20% of patients, typically mild and reversible upon discontinuation. Severe hepatic injury is rare (less than 1%), but increases occur dose-dependently, peaking around days 7-14 of treatment. This stems from its biliary excretion and potential mitochondrial toxicity in hepatocytes.[1][3]
How Often and When to Monitor?
- Baseline: Check ALT, AST, bilirubin, and alkaline phosphatase before starting.
- During treatment: Monitor weekly for courses longer than 14 days; more frequently (every 3-5 days) in hepatic impairment (Child-Pugh B/C) or with risk factors like alcohol use or concomitant hepatotoxins.
- Follow-up: Recheck 2-4 weeks post-treatment if elevations occurred.
Discontinue if transaminases exceed 5x upper limit of normal (ULN) or 3x ULN with symptoms/bilirubin >2x ULN.[1][4]
Who Needs Closer Monitoring?
Patients with:
- Pre-existing liver disease.
- Concurrent drugs like statins, acetaminophen, or other antibiotics.
- Obesity, diabetes, or prolonged therapy (>14 days).
No routine monitoring needed for short courses in healthy patients, but clinical judgment applies.[2][3]
What If Transaminases Rise?
Mild elevations (<3x ULN) often resolve without stopping therapy. For >5x ULN, hold tigecycline and investigate other causes (e.g., sepsis, ischemia). Recovery is typical within weeks; rechallenge is not recommended.[1][5]
Alternatives If Liver Concerns Exist
Switch to beta-lactams (e.g., piperacillin-tazobactam) or carbapenems for similar indications with lower hepatotoxicity risk. Consult ID specialist for MDR pathogens where tigecycline is preferred.[2][4]
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: IDSA Guidelines for Skin/Soft Tissue Infections
[3]: Hepatotoxicity Review - LiverTox (NIH)
[4]: FDA Drug Safety Communication on Tigecycline
[5]: Clinical Pharmacology Review - Tigecycline